The next generation of AI-powered clinical trials
TwinRCTs II™
Impact
Design and run AI-powered clinical trials with confidence
TwinRCTs II have all the enrollment benefits of TwinRCTs—but with even higher precision.
Accelerate time-to-market
AI-powered TwinRCTs hit enrollment targets faster because they require fewer patients to achieve the same power compared to traditional trial designs.
Attract patients
Many patients are wary of participating in clinical trials due to the prospect of receiving a placebo. TwinRCTs make control groups smaller, increasing a patients’s chance of receiving the experimental treatment.
Increase precision
Unlike first-generation TwinRCTs, patient digital twins in TwinRCTs II are emphasized or de-emphasized based on the confidence of the prediction, leading to an increase in trial power.
How it works
TwinRCTs II predict patient outcomes, as well as the confidence of those predictions
Generate patient digital twins
After a patient’s first clinical trial visit, our digital twin generator creates multiple probabilistic predictions of how that patient’s disease would progress over time if they received a placebo.
Calculate digital twin average and confidence
A patient’s predicted longitudinal disease progression is calculated as the mean of the distribution. In TwinRCTs II, the confidence of that prediction is also calculated by the spread of the distribution.
Design weighted trials that emphasize high-confidence digital twins
With TwinRCTs II, patient digital twins with high confidence are emphasized and ones with low confidence are de-emphasized, increasing trial power.
We work with innovators in pharma and biotech to accelerate clinical drug development today
